Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for chronic actinic dermatitis
ChiCTR2400090514Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Kunming Medical University
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dupilumab in chronic actinic dermatitis (CAD), sponsored by First Affiliated Hospital of Kunming Medical University. Primary endpoint: Eczema Area and Severity Index. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
03
Conditions
chronic actinic dermatitis (CAD)
Beyond the preview
Go deeper on ChiCTR2400090514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090514.